Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05746923

Lesser Poland Cracovian Heart Failure Registry

The goal of Lesser Poland Cracovian Heart Failure Registry (LECRA-HF) is to expand the knowledge about acute heart failure (AHF) and its long-term prognosis.

The main questions are:

* assessment of long-term prognosis of AHF and its determinants * determination of the optimal AHF treatment methods * assessment of indications for invasive coronary arteries diagnostics and revascularization and their long-term effects * analysis of the particular HF subtypes (HFimpEF, HFpEF, HFsnEF, HFrEF, HFmrEF)

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Coronary Disease and Heart Failure, John Paul II Hospital in Krakow, Jagiellonian University Medical College

Krakow, 31-202, Poland

Location status: Recruiting

Location contact

Aleksandra Karcińska, MD

SUB_INVESTIGATOR

Jadwiga Nessler, Prof.

PRINCIPAL_INVESTIGATOR

Jarosław Zalewski, Prof.

SUB_INVESTIGATOR

Karol Nowak, MD

CONTACT

[email protected]

12 614 22 18 ext. +48

Karol Nowak, MD

SUB_INVESTIGATOR

Konrad Stępień, MD

CONTACT

[email protected]

12 614 22 18 ext. +48

Konrad Stępień, MD

PRINCIPAL_INVESTIGATOR

Natalia Kachnic, MD

SUB_INVESTIGATOR

About this study

LECRA-HF is a registry of patients with acute heart failure (AHF) hospitalized in the Department of Coronary Disease and Heart Failure, John Paul II Hospital in Krakow, Jagiellonian University Medical College. So far, a small population of patients has been included in similar registries conducted in the Polish population. This did not allow to draw reliable conclusions about this diverse group of patients.

As part of the LECRA-HF registry, a comprehensive analysis of the clinical characteristics of patients is planned, taking into account their medical history, anthropometric measurements, results of electrocardiographic, imaging and laboratory tests, as well as the treatment used during the index hospitalization and after discharge. Their long-term prognosis will also be analyzed. LECRA-HF is a continuous registry, updated annually until 2026.

The data collected in the LECRA-HF will be used to distinguish and describe relatively new subtypes of HF (HFimpEF, HFsnEF) as well as to properly characterize that difficult and very diverse population with a serious long-term prognosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hospitalization due to acute heart failure
  • > 18 years of age

Exclusion criteria

  • inability to give informed consent to participate in the registry

Treatment and study plan

Primary outcomes

  1. All-cause mortality

    Time frame: 2 years

    Mortality due to all causes

Secondary outcomes

  1. Cardiovascular mortality

    Time frame: 2 years

    Mortality due to CV causes

  2. HF rehospitalizations

    Time frame: 2 years

    Rehospitalizations related to HF decompensation

Other outcomes

  1. LVEF increase >10% in the follow-up echocardiography

    Time frame: 2 years

    In accordance with HFimpEF definition

Study contacts

Contact information is provided by the study sponsor or research team.

Karol Nowak, MD

CONTACT

[email protected]

12 614 22 18 ext. +48

Konrad Stępień, MD

CONTACT

[email protected]

12 614 22 18 ext. +48

Sponsors and collaborators

Lead sponsor

Jagiellonian University

Other

Registry information

Acronym: LECRA-HF

Important dates

Study start
2023
Primary completion
2024
Study completion
2026
First posted
Feb 28, 2023
Registry last updated
Mar 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.